Ferring Pharmaceuticals, Inc.
Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00796289
- Locations
- 🇺🇸
Florida Fertility Institute, Clearwater, Florida, United States
🇺🇸All Women's Healthcare of Wesy Broward, Inc., Plantation, Florida, United States
🇺🇸A Woman's Center for Reproductive Medicine, Baton Rouge, Louisiana, United States
Extension Study of Semapimod 60 mg IV x 3 Days
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00741910
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT00739986
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱Free University (Vrije Universiteit), Amsterdam, Netherlands
🇧🇪Academic Hospital Gasthuisberg, Leuven, Belgium
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 119
- Registration Number
- NCT00740103
- Locations
- 🇺🇸
Long Island Clinical Research Associates, Great Neck, New York, United States
🇺🇸Gastroenterology Associates, Bristol, Tennessee, United States
🇩🇪Universitats Klinikum Heidelberg, Heidelberg, Germany
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT00738673
- Locations
- 🇩🇪
Wissenschaftskontor Nord, Rostock, Germany
🇩🇪Martini Klinik, Hamburg, Germany
🇩🇪Urologische Klinik, Planegg, Germany
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT00737789
- Locations
- 🇫🇷
Hôpital de Lyon Sud, Pierre-benite, France
🇫🇷CH Le raincy-Montfermeil, Montfermeil, France
🇧🇪Universitair Ziekenhuis Brussel, Brussels, Belgium
Open-Label, Randomised Parallel-Group Study
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2011-03-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Registration Number
- NCT00728533
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 554
- Registration Number
- NCT00615836
- Locations
- 🇺🇸
Radiant Research, Kansas City, Overland Park, Kansas, United States
🇺🇸Women's Health Research Group, LLC, Clearwater, Florida, United States
🇺🇸Urology of Virginia PC, Virginia Beach, Virginia, United States
Canadian Active & Maintenance Modified Pentasa Study
- Conditions
- Active Ulcerative ColitisRemission of Ulcerative Colitis
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 288
- Registration Number
- NCT00603733
- Locations
- 🇨🇦
Hilyard Place Building A, Saint John, New Brunswick, Canada
🇨🇦L'Hotel Dieu de Quebec, Quebec, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions
- Conditions
- In Vitro Fertilisation (IVF) Treatment
- Interventions
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT00587327
- Locations
- 🇪🇸
Institut Universitari Dexeus, Barcelona, Spain
🇪🇸IVI Madrid, Madrid, Spain
🇨🇿Institute for Reproductive Medicine and Endocrinology, Pilsen, Czechia